Badrilla Ltd is a UK based biotechnology company founded in 2003 that makes exceptional antibodies to cardiovascular protein and phospho-protein targets. Working with outstanding academic collaborators, we are developing new calibration technologies, which will enable the performance of genuinely quantitative western blotting. Badrilla Ltd has always strived to make positive contributions to the antibody market via thorough product validation and honest data presentation.
We were very pleased to be able to attend the 23rd Northern Cardiovascular Research Group meeting in Newcastle upon Tyne on the 21st April 2015. The meeting provided an excellent range of speakers and posters and there were some good opportunities for networking with existing and future collaborators alike.
There have been many recent advances in methodologies to detect the only reversible lipidation reaction of proteins, S-palmitoylation. This fatty acyl post translational modification has gained great interest in the research community as it is increasingly recognised as important in both health and in disease areas such as